| Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| T-cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The landscape of disease: mapping aplastic anemia |
|
Blood |
Aplastic Anemia |
| Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Diagnosis and classification of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
